# Citius Oncology, Inc.: overview CTOR · Nasdaq · CIK 1851484 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Sep 30 Pages: [Overview](/companies/ctor.md) · [Financials](/companies/ctor/financials.md) · [Filings](/companies/ctor/filings.md) · [Insiders](/companies/ctor/insiders.md) Latest reported revenue: [$1.5m](/filings/0001213900-26-090184.md) for Q3 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 14, 2026 (XBRL us-gaap:Revenues, accession 0001213900-26-090184). ## Last eight quarters | Line item | Unit | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | not reported | not reported | not reported | not reported | [3,944](/filings/0001213900-26-015877.md) | [1,667](/filings/0001213900-26-057841.md) | [1,494](/filings/0001213900-26-090184.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | [80.0%](/filings/0001213900-26-015877.md) | [80.3%](/filings/0001213900-26-057841.md) | [67.1%](/filings/0001213900-26-090184.md) | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | [(133.2%)](/filings/0001213900-26-015877.md) | [(1716.2%)](/filings/0001213900-26-057841.md) | [(583.5%)](/filings/0001213900-26-090184.md) | | Net margin | % | not reported | not reported | not reported | not reported | not reported | [(140.3%)](/filings/0001213900-26-090184.md) | [(1596.0%)](/filings/0001213900-26-090184.md) | [(597.4%)](/filings/0001213900-26-090184.md) | | Diluted EPS | $ per share | not reported | [(0.09)](/filings/0001213900-26-015877.md) | [(0.11)](/filings/0001213900-26-057841.md) | [(0.08)](/filings/0001213900-26-090184.md) | not reported | [(0.06)](/filings/0001213900-26-015877.md) | [(0.27)](/filings/0001213900-26-057841.md) | [(0.08)](/filings/0001213900-26-090184.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure. ## Last five fiscal years | Line item | Unit | FY2022 (2022-12-31) | FY2023 (2023-09-30) | FY2023 (2023-12-31) | FY2024 (2024-09-30) | FY2025 (2025-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [0.12](/filings/0001493152-24-014850.md) | [(0.19)](/filings/0001213900-24-113150.md) | [0.27](/filings/0001493152-24-014850.md) | [(0.31)](/filings/0001213900-25-125331.md) | [(0.34)](/filings/0001213900-25-125331.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ctor/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [ARMISTICE CAPITAL, LLC](/funds/1601086.md) | 2026-06-30 | $5.7m | 8,705,589 | | Reduced −483,266 | | [BANK OF AMERICA CORP /DE/](/funds/70858.md) | 2026-06-30 | $2.5m | 3,835,160 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $355.1k | 546,325 | | Added +11,501 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $217.5k | 334,619 | | Added +297,779 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $159.5k | 245,407 | | Reduced −19,326 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $79.2k | 121,910 | | Unchanged | | [IFP Advisors, Inc](/funds/1641866.md) | 2026-06-30 | $69.8k | 107,424 | | Unchanged | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $58.9k | 90,586 | | New +90,586 | | [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $29.7k | 45,746 | | Unchanged | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $27.9k | 42,900 | | Unchanged | ## Recent filings [All 266 filings](/companies/ctor/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-23 | 16:10 ET | [8-K](/filings/0001213900-26-112109.md) | 8.01 Other events | 0001213900-26-112109 | | 2026-09-29 | 16:30 ET | [8-K](/filings/0001213900-26-104694.md) | 5.07 Shareholder vote results | 0001213900-26-104694 | | 2026-08-26 | 09:00 ET | [DEF 14A](/filings/0001213900-26-093757.md) | Proxy statement, period 2026-09-29 | 0001213900-26-093757 | | 2026-08-14 | 16:35 ET | [10-Q](/filings/0001213900-26-090184.md) | Quarterly report, period 2026-06-30 | 0001213900-26-090184 | | 2026-08-14 | 16:35 ET | [8-K](/filings/0001213900-26-090182.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-26-090182 | | 2026-08-12 | 08:30 ET | [8-K](/filings/0001213900-26-088068.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001213900-26-088068 | | 2026-08-05 | 09:28 ET | [8-K](/filings/0001213900-26-085434.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-085434 | | 2026-06-04 | 16:30 ET | [SCHEDULE 13D/A](/filings/0001213900-26-065310.md) | Ownership report, active investor, amended | 0001213900-26-065310 | | 2026-06-01 | 16:30 ET | [8-K](/filings/0001213900-26-063530.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-063530 | | 2026-05-15 | 16:44 ET | [8-K](/filings/0001213900-26-057883.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-26-057883 | ## Latest annual report [Form 10-K for the fiscal year ended Sep 30, 2025](/filings/0001213900-25-125331.md), filed Dec 23, 2025. ## Forecast league Q4 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/ce12a45e-42e9-4637-b681-76bd6016e7c8) ## About the filer - CIK: 1851484 - Tickers: CTOR - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 26, 2026, 16:06 ET. No prices; not investment advice.